OR-AIRSHIP
24.9.2020 15:02:10 CEST | Business Wire | Press release
Customer engagement company Airship today announced that it has acquired ReplyBuy, a company that pioneered fully integrated solutions for payments over SMS. This move extends Airship’s platform beyond customer engagement to directly enable commerce, as well as power one-to-one customer conversations via two-way SMS. In addition, Airship plans to extend ReplyBuy’s technology to provide turnkey commerce and payments solutions across more marketing channels, messaging platforms and industry verticals.
The acquisition will provide companies of all sizes a single platform to create, manage and optimize cross-channel customer interactions and drive greater revenue more quickly. Airship’s real-time mobile data, predictive AI and unified approach to customer journeys ensures relevant messaging at the optimal time on customers’ preferred channels across app and web notifications, SMS, email, mobile wallet and more. Subsequent digital actions customers take, now including purchases and conversations over SMS, provide rich user-level insight for journey optimization as well as data enrichment of other business systems. A broad ecosystem will benefit from Airship’s expertise in real-time data streaming and bi-directional martech integrations, and from ReplyBuy’s tight coupling with CRM and sales solutions.
“For over a decade, Airship has been the driving force in helping many of the world’s largest and most disruptive brands succeed in digital transformation, and the acquisition of ReplyBuy opens up an exciting new chapter,” said Brett Caine, CEO and president, Airship. “With ReplyBuy, we will provide an additional way for customers to increase their revenue and deepen customer relationships with one-to-one conversations. We’re thrilled to welcome the ReplyBuy team to the Airship family.”
ReplyBuy helps more than 100 brands quickly and efficiently engage, converse and transact with customers, through a simple, streamlined SMS solution proven to increase sales. Professional and collegiate sports teams, as well as entertainment venues, use ReplyBuy for the easiest and fastest ticket sales possible, while companies across higher education, non-profit and service-based organizations have seen tremendous success streamlining fundraising, membership renewals and appointment bookings. Airship will continue to sell, enhance and support ReplyBuy’s solutions, as well as enrich the Airship Customer Engagement Platform with new commerce and conversational capabilities.
“Nobody directly connects more brands to mobile consumers than Airship,” said Brandon O’Halloran, CEO, ReplyBuy. “Joining Airship offers ReplyBuy the opportunity to serve the global market with a more comprehensive solution across more industries, and provide more valuable mobile customer experiences.”
Beyond technology, the ReplyBuy team brings unique know-how in commerce, payments, and ticketing that will accelerate Airship’s efforts to eliminate friction in mobile customer experiences. ReplyBuy CEO Brandon O’Halloran will become Airship’s GM of commerce and CTO & co-founder Anthony Saia will lead the commerce engineering team.
“Forrester estimates that digital touchpoints currently affect more than half of total US retail sales and almost as much of European retail sales … Empowering sales and service associates with digital tools that allow them to connect with their customers digitally through email, text, and video is a great step,” (Forrester Research, Inc., “Envisioning The Future Of Omnichannel Commerce,” June 11, 2020).
Recently, Airship was named a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category (tied) and the second highest score in the Current Offering category.
Among 18 vendors in Gartner’s 2019 Magic Quadrant for Mobile Marketing Platforms 1 , Airship was positioned highest in its ability to execute and also furthest for its completeness of vision in the Leaders quadrant overall. Airship received the highest Product Scores across all three Use Cases in Gartner’s 2019 Critical Capabilities for Mobile Marketing Platforms 2 , including the Acquisition, Engagement and Retention Use Cases.
1 Gartner “Magic Quadrant for Mobile Marketing Platforms ” by Mike McGuire, Charles Golvin, July 15, 2019
2 Gartner “Critical Capabilities for Mobile Marketing Platforms ” by Charles S. Golvin, Mike McGuire, October 21, 2019
Gartner Disclosure
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About ReplyBuy
ReplyBuy, an Airship company, makes it easy for consumers to instantly message and purchase from brands over SMS. Companies of all sizes leverage ReplyBuy’s solutions to unlock the potential of personalized text messaging for 1:1 conversations and friction-free transactions at scale. For more information, visit www.replybuy.com .
About Airship
Thousands of the world’s leading brands rely on Airship to spark closer connections with their customers through highly contextual and relevant interactions. Only Airship’s Customer Engagement Platform takes a mobile-first, data-led approach that enables brands to focus on individuals and their needs, not which marketing channels to use. Airship makes it much simpler and more effective to grow customer lifetime value in the omnichannel era.
With trillions of interactions intelligently orchestrated across mobile apps, mobile wallet, SMS, websites, and email, Airship optimizes the entire customer journey across all digital touchpoints at scale.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005258/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom